328 related articles for article (PubMed ID: 12830468)
1. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels.
Chen WT; Lin YF; Yu FC; Kao WY; Huang WH; Yan HC
Am J Kidney Dis; 2003 Jul; 42(1):158-66. PubMed ID: 12830468
[TBL] [Abstract][Full Text] [Related]
2. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
6. Association of in vitro oxidative stress, serum ferritin concentration and C-reactive protein in febrile emergency room patients.
Huang HH; Yan HC; Han CL; Yu FC; Kao WY; Chen WT
Clin Invest Med; 2005 Apr; 28(2):48-54. PubMed ID: 15909479
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
8. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
Tarng DC; Huang TP
Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease.
Nand N; Deshmukh AR; Mittal R
J Assoc Physicians India; 2017 Jul; 65(7):32-36. PubMed ID: 28792166
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients.
Tarng DC; Liu TY; Huang TP
Kidney Int; 2004 Aug; 66(2):820-31. PubMed ID: 15253739
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis.
Einerson B; Chaiyakunapruk N; Kitiyakara C; Maphanta S; Thamlikitkul V
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S134-46. PubMed ID: 21721439
[TBL] [Abstract][Full Text] [Related]
12. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
13. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.
Patruta SI; Edlinger R; Sunder-Plassmann G; Hörl WH
J Am Soc Nephrol; 1998 Apr; 9(4):655-63. PubMed ID: 9555668
[TBL] [Abstract][Full Text] [Related]
15. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.
Sezer S; Ozdemir FN; Yakupoglu U; Arat Z; Turan M; Haberal M
Artif Organs; 2002 Apr; 26(4):366-70. PubMed ID: 11952508
[TBL] [Abstract][Full Text] [Related]
16. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
18. Serial ferritin concentrations in hemodialysis patients receiving intravenous iron.
Kirschbaum B
Clin Nephrol; 2002 Jun; 57(6):452-6. PubMed ID: 12078949
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic antioxidants and iron status in ESRD patients on hemodialysis.
Lim PS; Chan EC; Lu TC; Yu YL; Kuo SY; Wang TH; Wei YH
Nephron; 2000 Dec; 86(4):428-35. PubMed ID: 11124590
[TBL] [Abstract][Full Text] [Related]
20. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
